Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | GRM6 | O15303 | 2/20 | 0.32 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.32 |
| ▸ | GRM3 | Q14832 | 2/20 | 0.32 |
| ▸ | TRIP13 | Q15645 | 1/20 | 0.31 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.31 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.31 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14647104 | 1.00 | MEN1 (0.39) | MEN1KMT2ASMN1; SMN2ALDH1A1POLB | |
| SCHEMBL1890337 | 0.78 | MEN1 (0.36) | MEN1KMT2AALDH1A1TSHR | |
| SCHEMBL11852634 | 0.77 | MEN1 (0.35) | MEN1KMT2AALDH1A1 | |
| SCHEMBL11062466 | 0.77 | TSHR (0.35) | MEN1KMT2ATSHRGRM6GRM2 | |
| SCHEMBL15265465 | 0.72 | MEN1 (0.30) | MEN1KMT2AALDH1A1 | |
| SCHEMBL12265748 | 0.71 | ALDH1A1 (0.38) | MEN1KMT2AALDH1A1HPGDTSHR | |
| SCHEMBL18031731 | 0.71 | ALDH1A1 (0.38) | MEN1KMT2AALDH1A1HPGDTSHR | |
| SCHEMBL18031740 | 0.71 | MEN1 (0.31) | MEN1KMT2AALDH1A1 | |
| SCHEMBL28682218 | 0.70 | ALDH1A1 (0.37) | MEN1KMT2ASMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL8467058 | 0.70 | ALDH1A1 (0.37) | MEN1KMT2ASMN1; SMN2ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7935669-B2 | Compounds for a controlled release of active molecules | FIRMENICH SA (CH) | 2011-05-03 | — | — | US | claimed |
| US-20090181878-A1 | COMPOUNDS FOR A CONTROLLED RELEASE OF ACTIVE MOLECULES | FIRMENICH SA | 2009-07-16 | — | — | US | claimed |
| EP-1460994-B1 | COMPOUNDS FOR A CONTROLLED RELEASE OF ACTIVE MOLECULES | FIRMENICH & CIE (CH) | 2008-10-01 | — | — | EP | claimed |
| US-20040220074-A1 | Compounds for a controlled release of active molecules | FIRMENICH SA (CH) | 2004-11-04 | — | — | US | claimed |
| EP-1460994-A2 | COMPOUNDS FOR A CONTROLLED RELEASE OF ACTIVE MOLECULES | FIRMENICH SA (CH) | 2004-09-29 | — | — | EP | claimed |
| WO-2003049666-A2 | COMPOUNDS FOR A CONTROLLED RELEASE OF ACTIVE MOLECULES | FIRMENICH SA (CH) | 2003-06-19 | — | — | WO | claimed |
| US-7935669-B2 | Compounds for a controlled release of active molecules | FIRMENICH SA (CH) | 2011-05-03 | — | — | US | disclosed |
| US-7723286-B2 | Compounds for a controlled release of active molecules | FIRMENICH SA (CH) | 2010-05-25 | — | — | US | disclosed |
| US-20090181878-A1 | COMPOUNDS FOR A CONTROLLED RELEASE OF ACTIVE MOLECULES | FIRMENICH SA | 2009-07-16 | — | — | US | disclosed |
| EP-1460994-B1 | COMPOUNDS FOR A CONTROLLED RELEASE OF ACTIVE MOLECULES | FIRMENICH & CIE (CH) | 2008-10-01 | — | — | EP | disclosed |
| US-20040220074-A1 | Compounds for a controlled release of active molecules | FIRMENICH SA (CH) | 2004-11-04 | — | — | US | disclosed |
| EP-1460994-A2 | COMPOUNDS FOR A CONTROLLED RELEASE OF ACTIVE MOLECULES | FIRMENICH SA (CH) | 2004-09-29 | — | — | EP | disclosed |
| WO-2003049666-A2 | COMPOUNDS FOR A CONTROLLED RELEASE OF ACTIVE MOLECULES | FIRMENICH SA (CH) | 2003-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220074-A1 | Compounds for a controlled release of active molecules | ACLY, PTGES, NOTUM | MEN1 4581/4885KMT2A 4426/4885SMN1; SMN2 4444/4885 |
| US-20090181878-A1 | COMPOUNDS FOR A CONTROLLED RELEASE OF ACTIVE MOLECULES | ACLY, PTGES, PPOX | MEN1 4691/4885KMT2A 4649/4885SMN1; SMN2 4611/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.